$0.51
+4.06%
2026-09-04 12:27:19 EDT+$0.02
의료
의료 - 의료 정보 서비스
NASDAQ
활발히 거래 중
BullFrog AI Holdings, Inc.는 소속된 제휴 법인들과 함께 고급 디지털 바이오제약 기업으로 기능합니다. 회사의 핵심 사명은 미국 내에서 특히 방대한 의료 및 ...
BullFrog AI Holdings, Inc.는 소속된 제휴 법인들과 함께 고급 디지털 바이오제약 기업으로 기능합니다. 회사의 핵심 사명은 미국 내에서 특히 방대한 의료 및 ...
Bullfrog AI Holdings, Inc. (NASDAQ: BFRG) is a healthcare technology and digital biopharmaceutical company focused on applying AI/ML to interpret large medical and healthcare datasets, with the intent of supporting drug discovery and development decisions. The company’s core mission is to use data-driven analytics to examine preclinical and clinical research information, which it packages into its proprietary AI/ML platform, bfLEAP. This “digital biopharmaceutical” approach positions Bullfrog AI as a technology-enabled partner to biomedical research efforts rather than a traditional single-asset pharma company. From a product/service perspective, the central offering is bfLEAP, an AI/ML platform designed to analyze research data comprehensively. The company also appears to build its pipeline and technical differentiation through intellectual property access and licensing agreements. For example, it has referenced collaborations/agreements that provide rights to use specific targeting technology (e.g., siRNA targeting Beta2-spectrin via a licensing arrangement with George Washington University). Bullfrog AI has also referenced partnerships that provide access to particular drug formulations (e.g., a mebendazole formulation associated with Johns Hopkins University) for investigation in oncology and other disease contexts. In terms of business model and costs, the company’s profile suggests an early-stage, R&D-intensive approach typical of platforms pursuing research-led therapeutic development. The provided financial signals indicate negative profitability and cash-flow dynamics: metrics such as negative operating/net/EBIT margins and negative return measures (e.g., return on assets and equity) are consistent with a company investing heavily before sustained commercial revenues. Accordingly, the company’s cost structure likely includes software/compute and data work tied to bfLEAP development, personnel and research expenses, plus costs associated with licensing/IP administration and research program execution. Key people and governance are led by Founder, Chairman, and CEO Vininder (Vin) Singh. The company is headquartered in Gaithersburg, Maryland, and operates within the healthcare/medical information services industry. Overall, Bullfrog AI’s “wishes” and strategic direction (inferred from its disclosures and platform/licensing emphasis) are to translate AI-driven dataset interpretation into actionable therapeutic insights and to advance AI-informed programs across multiple human conditions—particularly where data analysis and targeted therapeutic mechanisms can potentially improve development efficiency and likelihood of success.